The World Health Organization’s European chief said on May 20 he is concerned that the spread of monkeypox could accelerate in the region as people gather for parties and festivals over the summer months.
A man in Massachusetts became the first person reported to have a case of monkeypox in the United States since 2021. The man contracted monkeypox after traveling to Canada, although Quebec’s Ministry of Health and Social Services told CBC News that no cases had been reported to the agency. SIGA Technologies is prepared to provide treatment to those infected with monkeypox.
Child vaccination rates in the United States fell during the COVID-19 pandemic as many children skipped doctors appointments and states eased vaccine requirements during remote learning, according to a government study released on April 21.
The Biden administration wants to expand a federal COVID-19 tracking system created during the pandemic to provide a more detailed view of how respiratory and other infectious diseases are affecting patients and hospital resources, according to a draft of proposed rules reviewed by Reuters.
Janssen Pharmaceutical’s experimental vaccine for a respiratory syncytial virus (RSV) demonstrated an 80 percent efficacy level in adults over the age of 65 years.
Covid-19 probably can be eradicated globally, just like polio, according to research just published in BMJ Global Health. That assumes, however, that a high rate of vaccination occurs globally and that there is a quick response to emerging variants.
After the July 4 holiday, the U.S. Food and Drug Administration has several items on the regulatory agency’s immediate calendar, including a couple target action dates and an advisory committee hearing.
Infectious disease experts are weighing the need for booster shots of the Pfizer/BioNTech or Moderna mRNA-based vaccines for Americans who received Johnson & Johnson’s one-dose vaccine due to the increasing prevalence of the more contagious Delta coronavirus variant.
Lifebit Biotech Ltd. announced the beginning of a long-term partnership with Boehringer Ingelheim to utilize Natural Language Processing (NLP) and Artificial Intelligence (AI) for the detection and early reporting of global disease outbreaks using real-world data harvested from scientific publications and other open sources.
Thermo Fisher Scientific is acquiring Mesa Biotech for about $450 million in cash, and will pay an additional $100 million in cash after certain milestones are hit.